Left main coronary artery aneurysm revealed by syncopal ventricular tachycardia in a 28-year-old woman.

pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005;112:3384–3390. 45. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003;362:271–280. 46. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterollowering medications: implications for primary care. Am J Manag Care 1999;5:437–444. 47. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281–2286. 48. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317–325. 49. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey SG, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract 2005;55:838–845. 50. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81:40–46. 51. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.